Our results, obtained in a well-defined cohort of ERα-positive postmenopausal breast cancer patients treated in this way, also suggest that maspin status, by evenly dichotomising such patients, might emerge as a useful predictor of the response to endocrine therapy. This evidence concerns the gene SERPINB5 and breast cancer.